Testosterone for Women in Menopause: What the Evidence Actually Shows

Testosterone helps women in menopause for one well-studied reason: low sexual desire that causes personal distress, a condition clinicians call hypoactive sexual desire disorder (HSDD). The landmark 2019 Global Consensus Position Statement on Testosterone Therapy for Women — written by experts representing 10 medical societies including the International Menopause Society and The Endocrine Society — concluded there is strong evidence that appropriate testosterone treatment benefits sexual function. On average it produced about one additional satisfying sexual event per month and improved desire, arousal, orgasm, pleasure and sexual responsiveness while reducing sexual distress. Testosterone is a hormone women naturally produce in smaller amounts than men, and levels decline with age. It is important to be precise about what the evidence supports: the consensus statement found that HSDD is currently the only clinical indication for testosterone therapy in women. That precision matters because testosterone is often marketed for far more than the science backs.

Despite widespread marketing, the evidence does not support testosterone for energy, mood, depression, brain fog, muscle building, or bone density in women. The 2019 Global Consensus Statement specifically reviewed these claims and found insufficient evidence to recommend testosterone for any indication other than HSDD. This is a common source of confusion, because clinics sometimes prescribe testosterone pellets or high doses promising broad 'anti-aging' or 'vitality' benefits. Not only are those benefits unproven, but high doses can cause side effects like acne, unwanted hair growth, voice changes, and scalp hair loss — some of which can be permanent. If your main concerns are fatigue, low mood, or cognitive fog, the evidence points toward other approaches: estrogen-based hormone therapy where appropriate, sleep and exercise, and evaluation for thyroid or iron issues. Our guides on menopause brain fog and menopause depression cover those routes. Testosterone is a targeted tool for a specific problem, not a general menopause cure-all.

The cardinal safety rule is that testosterone for women should keep blood levels within the normal premenopausal female range — never male physiological doses. At those female-appropriate doses, the 2019 consensus found no evidence of serious adverse events. Problems arise when women are given male-strength preparations or unregulated compounded pellets that deliver supraphysiologic levels, which is when side effects like acne, hirsutism (excess hair), and voice deepening appear. Because no female-specific product is approved in the US, providers who prescribe it typically use a small, measured fraction of an approved male formulation (such as a transdermal gel) and monitor blood testosterone levels to keep them in range. A reasonable protocol involves checking a baseline level, starting low, rechecking after a few weeks, and assessing whether sexual function actually improved after 3–6 months — discontinuing if there is no benefit. This careful, monitored approach is very different from the high-dose pellet model some clinics use.

Yes, but only off-label, because no testosterone product is FDA-approved for women in the United States. The only country with an approved female testosterone product is Australia, where a cream called Androfeme was approved in 2020. In the US, a knowledgeable menopause-literate clinician can prescribe a measured dose of an approved male transdermal product, used at female-appropriate amounts with blood-level monitoring. Telehealth menopause platforms increasingly offer testosterone alongside estrogen and progesterone, though quality and monitoring vary, so it is worth choosing a provider who tests and follows your levels rather than one who prescribes a one-size-fits-all pellet. If you are weighing the broader hormone-therapy landscape, our breakdown of bioidentical versus synthetic HRT and our guide to the cheapest way to get HRT in 2026 can help you understand pricing and access. Always confirm that any provider plans to monitor your blood levels.

At female-appropriate doses with monitoring, current evidence is reassuring — the 2019 Global Consensus Statement found no signal of serious harm, including no clear evidence of increased breast or cardiovascular risk in the studies available. However, two honest caveats apply. First, most trials ran for 6 to 24 months, so very long-term safety data are limited; this is an area where the science is still maturing. Second, oral testosterone formulations are not recommended because they can negatively affect cholesterol — transdermal (skin) delivery is preferred. The biggest real-world safety risk is not the hormone itself but overdosing: women given male-strength doses can develop side effects, some irreversible. The sensible bottom line is that testosterone is a legitimate, evidence-based option for postmenopausal women with distressing low libido, used at the right dose, with the right monitoring, by a provider who understands the female range — and an unproven, potentially risky choice when used for other purposes or at high doses.